Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Interest Expenses (2016 - 2026)

Integra Lifesciences Holdings' Interest Expenses history spans 17 years, with the latest figure at $23.7 million for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 24.7% to $23.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $86.3 million, a 22.12% increase, with the full-year FY2025 number at $86.3 million, up 22.12% from a year prior.
  • Interest Expenses hit $23.7 million in Q4 2025 for Integra Lifesciences Holdings, up from $22.7 million in the prior quarter.
  • Over the last five years, Interest Expenses for IART hit a ceiling of $23.7 million in Q4 2025 and a floor of $11.7 million in Q1 2022.
  • Historically, Interest Expenses has averaged $15.4 million across 5 years, with a median of $13.1 million in 2021.
  • Biggest five-year swings in Interest Expenses: tumbled 41.37% in 2021 and later soared 49.64% in 2024.
  • Tracing IART's Interest Expenses over 5 years: stood at $12.1 million in 2021, then increased by 6.34% to $12.9 million in 2022, then rose by 6.65% to $13.8 million in 2023, then soared by 38.06% to $19.0 million in 2024, then rose by 24.7% to $23.7 million in 2025.
  • Business Quant data shows Interest Expenses for IART at $23.7 million in Q4 2025, $22.7 million in Q3 2025, and $21.0 million in Q2 2025.